Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Nowsheen S.

Semin Cancer Biol. 2015 Apr 16. pii: S1044-579X(15)00014-0. doi: 10.1016/j.semcancer.2015.02.006. [Epub ahead of print] Review.

PMID:
25892662
2.

Developing clinical research incentives for academic oncologists.

Holcombe RF, Hollinger K.

J Med Pract Manage. 2014 Nov-Dec;30(3):211-4.

PMID:
25807628
3.

AM last page. Improving health care quality: a polarity management perspective.

Holcombe RF.

Acad Med. 2015 Feb;90(2):259. doi: 10.1097/ACM.0000000000000595. No abstract available.

PMID:
25494402
4.

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.

Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh WK.

Cancer Chemother Pharmacol. 2014 Sep;74(3):465-71. doi: 10.1007/s00280-014-2518-5. Epub 2014 Jul 15.

PMID:
25023489
5.

A novel signaling pathway regulates colon cancer angiogenesis through Norrin.

Planutis K, Planutiene M, Holcombe RF.

Sci Rep. 2014 Jul 9;4:5630. doi: 10.1038/srep05630.

6.

Cancer clinical research: return on investment in the era of value-based purchasing.

Holcombe RF.

J Oncol Pract. 2014 Sep;10(5):327-8. doi: 10.1200/JOP.2014.001416. Epub 2014 Jun 17. No abstract available.

7.

Implementation of electronic chemotherapy ordering: an opportunity to improve evidence-based oncology care.

Adelson KB, Qiu YC, Evangelista M, Spencer-Cisek P, Whipple C, Holcombe RF.

J Oncol Pract. 2014 Mar;10(2):e113-9. doi: 10.1200/JOP.2013.001184. Epub 2013 Dec 26.

8.

Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.

Pintova S, Sidhu H, Friedlander PA, Holcombe RF.

Melanoma Res. 2013 Dec;23(6):498-501. doi: 10.1097/CMR.0000000000000017.

PMID:
24113862
9.
10.

Invasive colon cancer, but not non-invasive adenomas induce a gradient effect of Wnt pathway receptor frizzled 1 (Fz1) expression in the tumor microenvironment.

Planutis K, Planutiene M, Nguyen AV, Moyer MP, Holcombe RF.

J Transl Med. 2013 Feb 26;11:50. doi: 10.1186/1479-5876-11-50.

11.

Clinical pathways for pancreatic neuroendocrine tumors.

Alistar A, Sung M, Kim M, Holcombe RF.

J Gastrointest Cancer. 2012 Dec;43(4):532-40. doi: 10.1007/s12029-012-9397-y. Review.

PMID:
22661335
12.

Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

Dellinger TH, Planutis K, Jandial DD, Eskander RN, Martinez ME, Zi X, Monk BJ, Holcombe RF.

Gynecol Oncol. 2012 Aug;126(2):259-67. doi: 10.1016/j.ygyno.2012.04.026. Epub 2012 Apr 30.

13.
15.

Role of canonical Wnt signaling in endometrial carcinogenesis.

Dellinger TH, Planutis K, Tewari KS, Holcombe RF.

Expert Rev Anticancer Ther. 2012 Jan;12(1):51-62. doi: 10.1586/era.11.194. Review.

PMID:
22149432
16.

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ.

Cancer Chemother Pharmacol. 2011 Aug;68(2):539-45. doi: 10.1007/s00280-011-1671-3. Epub 2011 May 19.

PMID:
21594722
17.

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.

Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1595-602. doi: 10.1007/s00280-011-1657-1. Epub 2011 May 10.

18.

Wnt signaling and colon carcinogenesis: beyond APC.

Najdi R, Holcombe RF, Waterman ML.

J Carcinog. 2011 Mar 17;10:5. doi: 10.4103/1477-3163.78111.

19.

Mission-focused, productivity-based model for sustainable support of academic hematology/oncology faculty and divisions.

Holcombe RF, Hollinger KJ.

J Oncol Pract. 2010 Mar;6(2):74-9. doi: 10.1200/JOP.091075. Epub 2010 Feb 19.

20.

Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles.

Nguyen AV, Albers CG, Holcombe RF.

Int J Mol Med. 2010 Jul;26(1):121-5.

PMID:
20514431
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk